» Articles » PMID: 24957559

Normal Tissue Sparing in a Phase II Trial on Daily Adaptive Plan Selection in Radiotherapy for Urinary Bladder Cancer

Overview
Journal Acta Oncol
Specialty Oncology
Date 2014 Jun 25
PMID 24957559
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Background: Patients with urinary bladder cancer often display large changes in the shape and size of their bladder target during a course of radiotherapy (RT), making adaptive RT (ART) appealing for this tumour site. We are conducting a clinical phase II trial of daily plan selection-based ART for bladder cancer and here report dose-volume data from the first 20 patients treated in the trial.

Material And Methods: All patients received 60 Gy in 30 fractions to the bladder; in 13 of the patients the pelvic lymph nodes were simultaneously treated to 48 Gy. Daily patient set-up was by use of cone beam computed tomography (CBCT) guidance. The first 5 fractions were delivered with large, population-based (non-adaptive) margins. The bladder contours from the CBCTs acquired in the first 4 fractions were used to create a patient-specific library of three plans, corresponding to a small, medium and large size bladder. From fraction 6, daily online plan selection was performed, where the smallest plan covering the bladder was selected prior to each treatment delivery. A total of 600 treatment fractions in the 20 patients were evaluated.

Results: Small, medium and large size plans were used almost equally often, with an average of 10, 9 and 11 fractions, respectively. The median volume ratio of the course-averaged PTV (PTV-ART) relative to the non-adaptive PTV was 0.70 (range: 0.46-0.89). A linear regression analysis showed a 183 cm(3) (CI 143-223 cm(3)) reduction in PTV-ART compared to the non-adaptive PTV (R(2) = 0.94).

Conclusion: Daily adaptive plan selection in RT of bladder cancer results in a considerable normal tissue sparing, of a magnitude that we expect will translate into a clinically significant reduction of the treatment-related morbidity.

Citing Articles

Adaptive radiotherapy for muscle invasive bladder cancer: a retrospective audit of two bladder filling protocols.

Guel D, Laverick N, MacLaren L, MacLeod N, Glegg M, Lamb G Radiat Oncol. 2024; 19(1):92.

PMID: 39030548 PMC: 11264890. DOI: 10.1186/s13014-024-02484-9.


Empirical analysis of a plan-of-the-day strategy to approximate daily online reoptimization for prostate CBCT-guided adaptive radiotherapy.

Yock A, Cooney A, Morales-Paliza M, Shinohara E, Homann K J Appl Clin Med Phys. 2023; 25(1):e14221.

PMID: 38029380 PMC: 10795443. DOI: 10.1002/acm2.14221.


Triggering daily online adaptive radiotherapy in the pelvis: Dosimetric effects and procedural implications of trigger parameter-value selection.

Yock A, Ahmed M, Masick S, Morales-Paliza M, Kluwe C, Shinde A J Appl Clin Med Phys. 2023; 24(10):e14060.

PMID: 37276079 PMC: 10562041. DOI: 10.1002/acm2.14060.


Optimized Adaptive Radiotherapy with Individualized Plan Library for Muscle-Invasive Bladder Cancer Using Internal Target Volume Generation.

Jo Y, Yea J, Park J, Oh S, Won Park J Cancers (Basel). 2022; 14(19).

PMID: 36230598 PMC: 9564375. DOI: 10.3390/cancers14194674.


Pathway for radiation therapists online advanced adapter training and credentialing.

Shepherd M, Graham S, Ward A, Zwart L, Cai B, Shelley C Tech Innov Patient Support Radiat Oncol. 2021; 20:54-60.

PMID: 34917781 PMC: 8665404. DOI: 10.1016/j.tipsro.2021.11.001.